Monitor Q4 2025 results for the first full quarter of continuing operations post-LS&H divestiture, particularly organic recurring revenue growth trajectory and free cash flow generation against the $85M-$105M Q4 guidance. The 1.8% organic ACV growth and 1.3% organic recurring revenue growth are key metrics to track for sustained improvement.
Price Chart
How similar events traded
Executive Summary
Clarivate reported Q3 2026 adjusted EPS of $0.21, beating the $0.18 consensus by 16.7%, while continuing operations revenue of $481.6M missed the $490.1M consensus. The company completed the divestiture of its Life Sciences & Healthcare segment on October 6, 2026, and issued a full-year 2026 outlook for continuing operations with adjusted EPS of $0.73-$0.77 and revenue of $1.965B-$1.985B. Organic recurring revenue growth improved to 1.3% in Q3, but total continuing operations revenue declined 9.2% year-over-year due to inorganic disposals.
Key Financial Metrics
Key Facts
- Adjusted EPS of $0.21 beat consensus of $0.18 by 16.7%
- Continuing operations revenue of $481.6M missed consensus of $490.1M
- Total revenue including discontinued operations was $567.9M, down 8.9% YoY
- Organic revenue for continuing operations grew 0.4% YoY
- Organic recurring revenue (subscription + re-occurring) grew 1.3% YoY
- Organic ACV grew 1.8% compared to September 30, 2025
- Completed divestiture of Life Sciences & Healthcare segment on October 6, 2026 for net cash proceeds of $488.4M
- Full year 2026 outlook: revenue $1.965B-$1.985B, adjusted EBITDA $865M-$885M, adjusted EPS $0.73-$0.77
- Net loss of $80.8M including a $62.2M non-cash LS&H goodwill impairment charge
- Free cash flow for first nine months of 2026 was $233.1M, down from $276.1M in prior year period
Financial Impact
Adjusted EPS beat by $0.03 (16.7%); revenue miss of $8.5M (1.7%); LS&H divestiture proceeds of $488.4M; full year guidance implies ~$1.97B revenue and ~$0.75 adjusted EPS
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Academia & Government | $286.9M | -13.7% |
| Intellectual Property | $194.7M | -1.6% |
Risk Factors
- Continuing operations revenue declined 9.2% YoY driven by inorganic disposals, with transactional revenue down 57.9%
- Net loss widened to $80.8M from $28.3M due to $62.2M goodwill impairment
- Free cash flow declined 15.6% year-to-date versus prior year period
- Total debt remains high at $4.14B against a $1.1B market cap
- Document contains text addressed to automated readers
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302927273 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 4, 2026 today | 8-K | $1.62 | awaiting T+60 | awaiting T+60 | $2.33 (+43.52%) |
Nov 3, 2026 today | 144 | $2.08 | awaiting T+60 | awaiting T+60 | $2.33 (+11.61%) |
Nov 3, 2026 1d ago | 8-K | No price | awaiting T+60 | awaiting T+60 | No price |
Nov 3, 2026 1d ago | Press Release | $1.67 | awaiting T+60 | awaiting T+60 | $2.33 (+39.22%) |
Oct 13, 2026 21d ago | 8-K/A | $1.61 | awaiting T+60 | awaiting T+60 | $2.33 (+44.41%) |
Oct 6, 2026 28d ago | 8-K | $1.47 | awaiting T+60 | awaiting T+60 | $2.33 (+58.16%) |
Sep 24, 2026 5w ago | 8-K | $1.84 | awaiting T+60 | awaiting T+60 | $2.33 (+26.36%) |
Sep 22, 2026 6w ago | Press Release | $1.89 | awaiting T+60 | awaiting T+60 | $2.33 (+23.02%) |
Sep 17, 2026 6w ago | Press Release | $1.90 | awaiting T+60 | awaiting T+60 | $2.33 (+22.37%) |
Aug 10, 2026 12w ago | Insider Cluster | $1.91 | awaiting T+60 | awaiting T+60 | $2.33 (+21.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers